GA
NVCR icon

GFS Advisors’s NovoCure NVCR Stock Holding History

GFS Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204K Buy
+175
New +$2.65K 0.02% 188

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

GFS Advisors's NVCR Position: Q2 2026 in Review

GFS Advisors opened a new position in NovoCure (NVCR) in Q2 2026: 175 shares worth $204K. The stake represents 0.02% of the portfolio and ranks #188 among its holdings.

216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • GFS Advisors held 175 shares of NovoCure worth $204K as of Q2 2026.
  • NovoCure was a new GFS Advisors position in Q2 2026.
  • NovoCure made up 0.02% of GFS Advisors's portfolio in Q2 2026, its #188 holding.
  • 216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on GFS Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.